The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Key Takeaways U.S. equities were mixed at midday, slowed by new Chinese tariffs on U.S. goods and weak tech results.Alphabet ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

A young Wisconsin man died from an asthma attack after the price of his inhaler skyrocketed nearly $500, according to a ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target cells ...